As COVID-19 vaccination rates rise, government restrictions relax and businesses around the U.S. prepare to reopen, organizational leaders are exploring the path to “getting back to normal” that feels right for them, their associates, their customers, their industry and their community.   

BD has been at the forefront of the ongoing fight against COVID-19, and we continue to help bring our expertise, experience and assistance to support leaders in all kinds of businesses with our rapid antigen testing solutions.

BD’s new ‘BD On Location’ documentary-style series showcases how leaders across the country are navigating the complexities of reopening. The series will feature interviews with leaders from various industries, from sports to entertainment to hospitality, as well as insights from BD experts and other thought leaders, about how to get closer to “business as usual” while prioritizing public health and safety. 

BD on Location: Episode One – USA Track & Field

Episode One looks at how USA Track & Field (USATF) is going the extra mile to get athletes back on the track safely through the use of the BD Veritor™ Plus System – a portable, rapid and easy-to-use point-of-care antigen test that provides results in just 15 minutes on a simple, digital display. It includes interviews with several athletes, including Allyson Felix, the most decorated American female Olympian in track and field history; Max Siegel, CEO of USATF; Dr. Robert Chapman, Director of Sports Science and Medicine at USATF and Tom Polen, CEO of BD.

Check out the full episode at BDonLocation.com and be sure to stay tuned, as new episodes will be released regularly. Each one will focus on how different organizations are overcoming the challenges of the reopening process—and the role testing is playing in keeping their operations safe.

About BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2

The BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 Assay has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The test has been authorized by FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and the test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. For more information on the BD Veritor™ system, please visit bdveritor.com.